Saltar al contenido
Merck
  • Treatment outcomes in a cohort of Palestine refugees with diabetes mellitus followed through use of E-Health over 3 years in Jordan.

Treatment outcomes in a cohort of Palestine refugees with diabetes mellitus followed through use of E-Health over 3 years in Jordan.

Tropical medicine & international health : TM & IH (2013-12-18)
Ali Khader, Ghada Ballout, Yousef Shahin, Majed Hababeh, Loai Farajallah, Wafaa Zeidan, Ishtaiwi Abu-Zayed, Arata Kochi, Anthony D Harries, Rony Zachariah, Anil Kapur, Irshad Shaikh, Akihiro Seita
RESUMEN

The aim of this study was to use E-Health to report on 12-month, 24-month and 36-month outcomes and late-stage complications of a cohort of Palestine refugees with diabetes mellitus (DM) registered in the second quarter of 2010 in a primary healthcare clinic in Amman, Jordan. Retrospective cohort study with treatment outcomes censored at 12-month time points using E-Health in UNRWA's Nuzha Primary Health Care Clinic. Of 119 newly registered DM patients, 61% were female, 90% were aged ≥40 years, 92% had type 2 DM with 73% of those having hypertension and one-third of patients were newly diagnosed. In the first 3 years of follow-up, the proportion of clinic attendees decreased from 72% to 64% and then to 61%; the proportion lost to-follow-up increased from 9% to 19% and then to 29%. At the three time points of follow-up, 71-78% had blood glucose ≤180 mg/dl; 63-74% had cholesterol <200 mg/dl; and about 90% had blood pressure <140/90 mmHg. Obesity remained constant at 50%. The proportion of patients with late-stage complications increased from 1% at baseline to 7% at 1 year, 14% at 2 years and 15% at 3 years. Nuzha PHC Clinic was able to monitor a cohort of DM patients for 3 years using E-Health and the principles of cohort analysis. This further endorses the use of cohort analysis for managing patients with DM and other non-communicable diseases.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Colesterol, Sigma Grade, ≥99%
Sigma-Aldrich
Colesterol, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
Colesterol, from sheep wool, ≥92.5% (GC), powder
Sigma-Aldrich
SyntheChol® NS0 Supplement, 500 ×, synthetic cholesterol, animal component-free, aqueous solution, sterile-filtered, suitable for cell culture
SAFC
Colesterol, derivado vegetal, SyntheChol®
Supelco
Cholesterol solution, certified reference material, 10 mg/mL in chloroform
Sigma-Aldrich
Colesterol, tested according to Ph. Eur.